ClinicalTrials.gg

Program

VRC07-523LS

Also written as “TMB-380”, “VRC07523LS” and “TMB-365/TMB-380”.

Its studies are led by 2 companies.

Furthest: phase 2, since Mar 2, 20223 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
TaiMed Biologics21 open or runningphase 2since Mar 2, 2022Mar 2, 2022May 2027phase 2 · NCT07215468
Gilead Sciences10 open or runningphase 2since Mar 7, 2022Mar 7, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2022First study: phase 2 study in HIV-1-infectionNew to TaiMed BiologicsTaiMed Biologics · NCT05275998 · 51 enrolled · United States
  2. Mar 7, 2022Gilead Sciences's first study: phase 2 study in HIV-1-infectionNew to Gilead SciencesGilead Sciences · NCT05281510 · 20 enrolled · South Africa
  3. Oct 9, 2025Phase 2 study in HIV -1 InfectionTaiMed Biologics · NCT07215468 · 88 enrolled · United States

Ahead

  1. May 2027Primary completion: phase 2 study in HIV -1 InfectionTaiMed Biologics · NCT07215468

TargetBeta

CD4 →read by rule
“VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope.”study text, by rule · the study

Other programs on CD4

ProgramCompanyFurthest phaseStudies
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
TMB-365ruleTaiMed Biologicsphase 23
Allogeneic BAFF-L-expressing CAR T Cells LMY-922ruleLuminary Therapeuticsphase 12

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07215468HIV -1 Infection · United States2Active, not recruitingTaiMed BiologicsMay 202788
NCT05281510HIV-1-infection · South Africa2CompletedGilead SciencesJan 16, 202520
NCT05275998HIV-1-infection · United States2CompletedTaiMed BiologicsNov 20, 202451

How it is read

Names in the registry

  • “TMB-380”, 1 entry
  • “VRC07523LS”, 1 entry
  • “TMB-365/TMB-380”, 1 entry

Codes read as this program: TMB380.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.